November 3, 2025 · Form 4 insider transaction
GADICKE ANSBERT sold 94,063 shares of Werewolf Therapeutics, Inc. at $1.29 per share, a transaction worth $121.3K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 0 days after the transaction.
Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.; The shares were sold as follows: 6,458 by AM LLC, 40,800 by BV 2014, 2,721 by BV 2014(B), 1,405 by AM BV2014, 8,985 by MPM OIF and 33,694 by UBS Oncology.; The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.245 to $1.33 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.; The shares are held as follows: 422,201 by AM LLC, 2,666,424 by BV 2014, 177,846 by BV 2014(B), 91,778 by AM BV2014, 585,110 by MPM OIF and 2,204,251 by UBS Oncology.